Dossier · Legal analysis · 2026-05-24
Those who operate today may answer in court tomorrow
News — 17 June 2026
FTC and four states sue WPATH over allegedly deceptive claims about pediatric medical transition — the federal complaint alleges the Standards of Care misled parents about necessity, safety and effectiveness; WPATH calls the lawsuit baseless (source).
Why Dutch physicians who continue gender-affirming medical treatment on minors stand on increasingly thin legal ice — a warning and an analysis.
Core
Since 2020 the international evidence base for puberty blockers and cross-sex hormones in minors has been assessed as weak in several Western countries: NICE (UK, 2020) rated the evidence for puberty blockers "very low certainty" (source), and according to the Cass Review the Finnish and Swedish guidelines recommend medical treatment only within a research framework (source). The Cass Review (April 2024) found insufficient and/or inconsistent evidence on psychological and psychosocial effects (source). In December 2024 a research group from Amsterdam UMC, including child psychiatrist Annelou de Vries, published a critical reflection in BMC Medical Ethics on how "effective" outcomes are framed in the evidence behind the WPATH Standards of Care 8; of the 16 articles analysed, 15 highlight the limited evidence base, and the authors call for an explicit discussion of the objectives of treatment (source). Whether this changes the legal position of Dutch physicians is a legal question that this page raises but does not settle.
A turning point physicians cannot ignore
In April 2024 the British pediatrician Hilary Cass published her final report on medical care for children and young people with gender dysphoria.1 The conclusion: the scientific basis for puberty blockers and cross-sex hormones in minors is weak. Earlier, Sweden and Finland had issued guidelines that, according to the Cass Review, recommend medical treatment only within a research framework (source), and in March 2024 NHS England decided that puberty blockers are no longer available as a routine commissioning treatment option for under-18s (source).
The Netherlands — the country where the Dutch Protocol was developed — has so far kept its approach: on 30 June 2026 the Gezondheidsraad wrote that Dutch care is carefully organised and saw no reason to organise it differently, while rating the evidence for effects "low to very low" (source). In December 2024 a research group at Amsterdam UMC published an article in BMC Medical Ethics that analyses how "effective" outcomes are framed in the research cited in the WPATH Standards of Care 8.2 The article mentions, citing other authors, the proposal to justify treatment through personal desire and autonomy, analogous to abortion and birth control, but states that it does not propose a definitive answer (source).
The timeline of the turning point
Dutch courts measure a physician's conduct against the professional standard; in the Trombose ruling of 2 March 2001 the Supreme Court (Hoge Raad) dealt with the liability of a hospital that had not followed its own thrombosis protocol.3 Whether, and from when, developments in the evidence change that standard for gender care is a legal question that this page does not answer.
- 2020 — Finland issues a guideline (COHERE) that, according to the Cass Review, recommends medical treatment, given the lack of evidence, only within a research framework.4
- 2020 — NICE (UK) evidence reviews, dated October 2020, rate the certainty of the evidence for puberty blockers and cross-sex hormones as very low.5 (source)
- 2020 — In Bell v Tavistock the Divisional Court holds that it is highly unlikely that under-13s could be competent to consent to puberty blockers and very doubtful for 14- and 15-year-olds; the Court of Appeal overturns this on 17 September 2021, holding that it is for clinicians, not judges, to assess competence.6 (source)
- 2022 — SBU (February) finds the evidence for hormone treatment insufficient (source); Socialstyrelsen (December) gives a weak negative recommendation for puberty blockers and cross-sex hormones in minors (source).7
- 2024 — The Cass Review appears: 388 pages of research, commissioned by NHS England.1
- 2024 — Oosthoek et al. (Amsterdam UMC) publish in BMC Medical Ethics a critical reflection on how "effective" outcomes are framed in the evidence behind the WPATH Standards of Care 8.2
- March 2024 — NHS England decides that puberty blockers are no longer available as a routine commissioning treatment option for under-18s. (source)
Whether Dutch physicians who continue to prescribe puberty blockers could later be held liable is a legal question on which this page takes no position beyond pointing to the developments listed above.
Continue in this dossier
Three legal tracks
Civil law (Wgbo), disciplinary law (BIG Act) and criminal law — what each track can and cannot do.
Informed consent as the strongest route
Five elements on which the duty of disclosure in gender care structurally falls short.
Defenses parried — and what to do today
How the standard defenses (guideline, signature, WPATH, suicide risk, ex tunc) are countered — and the action agenda for the physician.
Smeehuijzen — legal objections
Why the Dutch Protocol does not hold up as a legal yardstick.
Notes
- Cass H. The Cass Review: Independent Review of Gender Identity Services for Children and Young People — Final Report. NHS England, April 2024.
- Oosthoek ED, Stanwich S, Gerritse K, Doyle DM, de Vries ALC. Gender-affirming medical treatment for adolescents: a critical reflection on "effective" treatment outcomes. BMC Medical Ethics. 2024;25. doi:10.1186/s12910-024-01143-8
- Hoge Raad 2 March 2001, ECLI:NL:HR:2001:AB0377 (Trombose): liability of a hospital that had not followed its own thrombosis protocol. rechtspraak.nl
- COHERE Finland. Recommendation of the Council for Choices in Health Care on medical treatment methods for variations of gender identity in minors. June 2020.
- NICE. Evidence review: Gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria and Evidence review: Gender-affirming hormones for children and adolescents with gender dysphoria. October 2020.
- Bell v Tavistock [2020] EWHC 3274 (Admin); reversed on procedural grounds in [2021] EWCA Civ 1363.
- Socialstyrelsen. Vård av barn och ungdomar med könsdysfori — nationellt kunskapsstöd. December 2022. SBU. Hormone treatment of children and adolescents with gender dysphoria, report 342, February 2022.
This piece is a legal analysis for a general audience and does not constitute individual legal advice. For concrete matters, specialized medico-legal counsel is advised.